These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1947761)

  • 1. Serum tumour markers in clinical practice. Some general aspects.
    Kvinnsland S
    Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of tumour markers in clinical practice].
    Keuren JF; Thomas CM; Bonfrèr JM; Sweep CG; Boonstra JG
    Ned Tijdschr Geneeskd; 2009; 153():A617. PubMed ID: 19857306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour markers.
    Pandha HS; Waxman J; Sikora K
    Br J Hosp Med; 1994 Mar 16-Apr 5; 51(6):297-303. PubMed ID: 8032568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Criteria for using tumor markers. 2: Indications and interpretation].
    Fateh-Moghadam VA; Stieber P
    Fortschr Med; 1996 Mar; 114(7):38-40. PubMed ID: 8900968
    [No Abstract]   [Full Text] [Related]  

  • 8. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer.
    Cordero OJ; De Chiara L; Lemos-González Y; Páez de la Cadena M; Rodríguez-Berrocal FJ
    Anticancer Res; 2008; 28(4C):2333-41. PubMed ID: 18751415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
    Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
    Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers--how they should be applied].
    Stieber P; Heinemann V; Schalhorn A
    MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour markers: their use and misuse by clinicians.
    McGinley PJ; Kilpatrick ES
    Ann Clin Biochem; 2003 Nov; 40(Pt 6):643-7. PubMed ID: 14629802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumour markers in malignant diseases].
    Ottó S; Ferencz A
    Magy Onkol; 2004; 48(1):13-20. PubMed ID: 15105891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
    Lindmark G; Kressner U; Bergström R; Glimelius B
    Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of molecular markers of oral cancer--a review.
    Schliephake H
    Int J Oral Maxillofac Surg; 2003 Jun; 32(3):233-45. PubMed ID: 12767868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases.
    Hasholzner U; Stieber P; Zimmermann A; Burges A; Hofmann K; Schmitt UM; Schmeller N; Schalhorn A
    Anticancer Res; 1999; 19(4A):2415-20. PubMed ID: 10470168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.